Metachronous Carcinoma of the Vulva and Fallopian Tube

Ichikawa, Yoshihito; Tsunoda, Hajime; Nishide, Ken; Nishida, Masato; Kubo, Takeshi

doi:10.1006/gyno.2000.5726

Cited by 7 publications

(6 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metastatic disease was evaluated, and it was conclusively determined via local and consultative pathologists that the tumors were histologically separate primaries. Findings of cocancers had been described for vaginal and vulvar cancers (49) , but few studies have documented this occurrence with fallopian tube cancers (23) . These patients with synchronous gynecological carcinomas may have a hereditary cancer syndrome predisposing them to reproductive tract cancers (BRCA1, BRCA2, HNPCC syndromes) or have acquired a transforming virus via urogenital passage.…”

Section: Discussionmentioning

confidence: 99%

“…A number of patients, as well, had carcinomas occurring at times distant to their fallopian tube cancer. Im-provements in the treatment of cancer have increased survival rates and survival time but have also increased the number of patients developing a second primary carcinoma (23) . Four (12.4%) patients in this study had a history of breast cancer.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A 10-year review of primary fallopian tube cancer at a community hospital: a high association of synchronous and metachronous cancers

Benoit

Hannigan

2006

Int J Gynecol Cancer

View full text Add to dashboard Cite

Primary fallopian tube carcinomas (PFTC) are rare gynecological tumors infrequently diagnosed prior to operative intervention. A retrospective review was performed to characterize the distribution and clinicopathologic significance of these tumors. Identification of PFTC was achieved through a review of the tumor registry and medical record ICD-9 codes at a community teaching hospital. A total of 1.5% of all gynecological cancers were PFTC. Most patients were presumed to have ovarian cancer. Ultrasound had the highest sensitivity (82%) for preoperative diagnosis. Surgical exploration was needed for definitive diagnosis in all patients. Optimal debulking was predictive of survival and of a negative second-look laparotomy (P < 0.05). Twenty-five percent of patients had a metachronous cancer diagnosed prior to their fallopian tube cancer, and 22% had a synchronous gynecological malignancy diagnosed at the time of surgical exploration. The response rate to platinum-based chemotherapy was 78%. The 5-year survival rate was 87%, and the overall survival rate was 75%. The median follow-up was 38 months. This report details the diagnostic and therapeutic experience of patients with PFTC and describes the occurrence of synchronous and metachronous gynecological cancers.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

A 10-year review of primary fallopian tube cancer at a community hospital: a high association of synchronous and metachronous cancers

Benoit

Hannigan

2006

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…Several studies also included Paclitaxel in the first line therapy (McMurray et al, 1986;Maxson et al, 1987;Muntz et al, 1991;Ben-Hur et al, 1999;Gemignani et al, 2001). For relapse therapy, data from epithelial ovarian cancer in platinum-pretreated patients also highlights the role of Paclitaxel (Tresukosol et al, 1995;Baekelandt et al, 2000;Ichikawa et al, 2000;Gemignani et al, 2001). After review of the literature and according to the U.S. guidelines, Pectasides and colleagues suggested an adjuvant standard treatment shown in table 3 (Pectasides et al, 2006).…”

Section: Treatmentmentioning

confidence: 99%

Fallopian tube tumors: an overview

Stein¹,

Diessner²,

Hönig³

et al. 2013

Atlas of Genetics and Cytogenetics in Oncology and Haematology

View full text Add to dashboard Cite

“…Paclitaxel has been shown to have activity in platinum-pretreated patients with PFTC [104][105][106][107]. Tresukosol et al [106] reported that paclitaxel at a dose of 200 mg/m 2 produced a complete response in a patient with recurrent platinum-resistant disease, and Ichikawa et al [107] reported that the combination of carboplatin (AUC 6) plus paclitaxel (180 mg/m 2 ) achieved a complete response in a patient with a platinum-pretreated tumor. In EOC, there is evidence that using intraperitoneal therapy as one component may be more effective than i.v.…”

Section: Combination Chemotherapy For Advanced Diseasementioning

confidence: 99%

Fallopian Tube Carcinoma: A Review

2006

View full text Add to dashboard Cite

Purpose. Primary fallopian tube carcinoma (PFTC) is a rare tumor that histologically and clinically resembles epithelial ovarian cancer (EOC). The purpose of this study is to review the current available literature data on PFTC.Patients and Results. Early clinical manifestation and prompt investigation often lead to diagnosis at an early stage of disease. However, the diagnosis of PFTC is rarely considered preoperatively and is usually first appreciated by the pathologist. Surgical staging/management and the use of chemotherapy follow the concepts used in epithelial ovarian cancer (EOC). In contrast to EOC is the importance of early lymphatic spread in this disease. The earlier diagnosis of PFTC leads to an apparent better survival compared with EOC. However, as with EOC, stage and residual tumor are the most important prognostic variables.Conclusion. Until more extensive clinical research has been performed, ovarian carcinoma management principles should be used in clinical practice. The Oncologist 2006;11:902-912

show abstract

Metachronous Carcinoma of the Vulva and Fallopian Tube

Cited by 7 publications

References 4 publications

A 10-year review of primary fallopian tube cancer at a community hospital: a high association of synchronous and metachronous cancers

A 10-year review of primary fallopian tube cancer at a community hospital: a high association of synchronous and metachronous cancers

Fallopian tube tumors: an overview

Fallopian Tube Carcinoma: A Review

Contact Info

Product

Resources

About